Does the nicotine metabolite ratio moderate smoking cessation treatment outcomes in real-world settings? A prospective study.

ABSTRACT:

Background and aims

In smoking treatment trials comparing varenicline with transdermal nicotine replacement therapy (NRT), stratified by nicotine metabolite (3-hydroxycotinine/cotinine) ratio (NMR), the relative benefit of varenicline is greater among normal rather than slow metabolizers. This study tested if the relative effectiveness of varenicline and NRT is associated with NMR status in a natural treatment setting. A secondary aim was to test if this relationship is moderated by behavioural support.

Design

Prospective observational multi-centre study with 4-week and 52-week follow-up.

Setting

Nine English Stop Smoking Services (SSS).

Participants

Data came from 1556 smokers (aged ≥ 16 years) attending SSS between March 2012 and March 2013.

Interventions<

SUBMITTER: Shahab L 

PROVIDER: S-EPMC6492100 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature